Technical Analysis for NVAX - Novavax, Inc.

Grade Last Price % Change Price Change
grade B 7.84 18.43% 1.22
NVAX closed up 18.43 percent on Friday, August 16, 2019, on 6.35 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical NVAX trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Parabolic Rise Strength 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%

Older signals for NVAX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
Medicine Biopharmaceutical Medical Specialties Infectious Diseases Influenza Vaccination Vaccines Influenza Vaccine Rabies Seasonal Influenza H5n1 Clinical Trials Virus Like Particle
Is NVAX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 51.6
52 Week Low 4.01
Average Volume 882,648
200-Day Moving Average 21.0921
50-Day Moving Average 5.0318
20-Day Moving Average 4.7575
10-Day Moving Average 5.107
Average True Range 0.5952
ADX 24.16
+DI 50.7338
-DI 10.0432
Chandelier Exit (Long, 3 ATRs ) 6.4544
Chandelier Exit (Short, 3 ATRs ) 5.7956
Upper Bollinger Band 6.6295
Lower Bollinger Band 2.8855
Percent B (%b) 1.32
BandWidth 78.696795
MACD Line 0.3037
MACD Signal Line -0.0743
MACD Histogram 0.378
Fundamentals Value
Market Cap 2.27 Billion
Num Shares 290 Million
EPS -0.77
Price-to-Earnings (P/E) Ratio -10.18
Price-to-Sales 13.78
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.15
Resistance 3 (R3) 10.03 9.13 9.77
Resistance 2 (R2) 9.13 8.55 9.20 9.64
Resistance 1 (R1) 8.49 8.18 8.81 8.61 9.51
Pivot Point 7.59 7.59 7.76 7.66 7.59
Support 1 (S1) 6.95 7.01 7.27 7.07 6.17
Support 2 (S2) 6.05 6.64 6.12 6.04
Support 3 (S3) 5.41 6.05 5.92
Support 4 (S4) 5.53